Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.78 |
| ▸ | JAK2 | O60674 | 2/20 | 0.78 |
| ▸ | RET | P07949 | 2/20 | 0.78 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.78 |
| ▸ | CDK1 | P06493 | 2/20 | 0.78 |
| ▸ | ROS1 | P08922 | 2/20 | 0.78 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.78 |
| ▸ | CDK2 | P24941 | 2/20 | 0.78 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.78 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.78 |
| ▸ | CLK2 | P49760 | 2/20 | 0.78 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.78 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.78 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.78 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.78 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.78 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.78 |
| ▸ | CDC7 | O00311 | 1/20 | 0.78 |
| ▸ | PLK4 | O00444 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17911543 | 1.00 | KDR (0.78) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL4826083 | 1.00 | KDR (0.78) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL29999054 | 0.94 | JAK2 (0.86) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL24096480 | 0.94 | JAK2 (0.86) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL28420737 | 0.92 | KDR (0.70) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL17235877 | 0.92 | KDR (0.70) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL30321053 | 0.88 | KDR (0.77) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL1318717 | 0.88 | SRC (0.77) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL29590269 | 0.88 | SRC (0.77) | KDRJAK2RETDYRK3CDK1 | |
| SCHEMBL401336 | 0.88 | KDR (0.77) | KDRJAK2RETDYRK3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-9861636-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-01-09 | — | — | US | disclosed |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138842-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-9532990-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-01-03 | — | — | US | disclosed |
| US-20160200730-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2016-07-14 | — | — | US | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200730-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | KDR 674/4885JAK2 17/4885RET 259/4885 |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | KDR 836/4885JAK2 1515/4885RET 356/4885 |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | KDR 674/4885JAK2 17/4885RET 259/4885 |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | KDR 674/4885JAK2 17/4885RET 259/4885 |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | BTK, LCK, LYN | KDR 674/4885JAK2 17/4885RET 259/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | KDR 1166/4885JAK2 1212/4885RET 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.